The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Vaccines for the 21st Century: A Tool for Decisionmaking
Table A19–1 Disease Scenarios for Parainfluenza Virus Infection
% of Cases
Committee HUI Values
Duration (years)
Upper Respiratory
70.00%
pharyngitis, otitis media
0.90
0.0192 (7 days)
Croup
19.20%
outpatient only
0.75
0.0274 (10 days)
Croup
0.80%
inpatient
0.50
0.0192 (7 days)
outpatient
0.75
0.0082 (3 days)
Bronchiolitis/pneumonia
9.60%
outpatient only
0.75
0.0274 (10 days)
Bronchiolitis/pneumonia
0.40%
inpatient
0.50
0.0192 (7 days)
outpatient
0.75
0.0082 (3 days)
Upper Respiratory
90.00%
0.90
0.0192 (7 days)
Bronchiolitis/pneumonia
10.00%
0.75
0.0274 (10 days)
Upper Respiratory
90.00%
0.90
0.0192 (7 days)
Bronchiolitis/pneumonia
9.60%
0.75
0.0274 (10 days)
Bronchiolitis/pneumonia
0.40%
inpatient
0.50
0.0192 (7 days)
outpatient
0.75
0.0082 (3 days)
COST INCURRED BY DISEASE
Table A19–2 summarizes the health care costs incurred by PIV infections. For the purposes of the calculations in this report, it was assumed that all children 2 years of age and under with PIV disease receive medical treatment. It was assumed that only 50% of people between the ages of 2 and 64 receive treatment for PIV disease. It was also assumed that only 50% of people 65 years of age and older receive treatment for mild (requiring only outpatient treatment if treated) pharyngitis and bronchiolitis. A small number of people age 65 years of age and older are hospitalized for bronchiolitis and pneumonia.
Pharyngitis, otitis media, croup, and outpatient treatment of bronchiolitis/pneumonia were assumed to be associated with physician visits, diagnostics and medications. The more serious disease incurred more visits to the physician. Hospitalization costs are included for the small number of people with PIV disease who require it.
